このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

iCAD 将来の成長

Future 基準チェック /16

iCADは、25.8%と18%でそれぞれ年率25.8%で利益と収益が成長すると予測される一方、EPSはgrowで26.2%年率。

主要情報

25.8%

収益成長率

26.2%

EPS成長率

Healthcare Services 収益成長	26.8%
収益成長率	18.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 May 2024

今後の成長に関する最新情報

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

業績と収益の成長予測

NasdaqCM:ICAD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	29	-2	N/A	N/A	2
12/31/2025	24	-5	N/A	N/A	2
12/31/2024	19	-6	N/A	N/A	3
3/31/2024	18	-5	-6	-5	N/A
12/31/2023	17	-7	-6	-5	N/A
9/30/2023	25	-13	-7	-7	N/A
6/30/2023	26	-15	-8	-8	N/A
3/31/2023	17	-9	-10	-10	N/A
12/31/2022	20	-10	-13	-13	N/A
9/30/2022	23	-12	-12	-11	N/A
6/30/2022	28	-11	-11	-11	N/A
3/31/2022	33	-13	-11	-10	N/A
12/31/2021	34	-11	-10	-9	N/A
9/30/2021	36	-9	-9	-9	N/A
6/30/2021	34	-8	-10	-9	N/A
3/31/2021	32	-7	-10	-9	N/A
12/31/2020	30	-18	-7	-7	N/A
9/30/2020	29	-19	-9	-8	N/A
6/30/2020	29	-21	-9	-8	N/A
3/31/2020	31	-22	-7	-7	N/A
12/31/2019	31	-14	-7	-7	N/A
9/30/2019	29	-14	-7	-6	N/A
6/30/2019	27	-12	-5	-5	N/A
3/31/2019	26	-9	-5	-5	N/A
12/31/2018	26	-9	-4	-4	N/A
9/30/2018	27	-10	-4	-4	N/A
6/30/2018	27	-15	-6	-6	N/A
3/31/2018	28	-17	-7	-6	N/A
12/31/2017	28	-14	N/A	-7	N/A
9/30/2017	27	-13	N/A	-7	N/A
6/30/2017	26	-9	N/A	-6	N/A
3/31/2017	27	-8	N/A	-5	N/A
12/31/2016	26	-10	N/A	-5	N/A
9/30/2016	27	-9	N/A	-6	N/A
6/30/2016	31	-7	N/A	-5	N/A
3/31/2016	34	-33	N/A	-4	N/A
12/31/2015	42	-32	N/A	-2	N/A
9/30/2015	48	-30	N/A	3	N/A
6/30/2015	50	-29	N/A	6	N/A
3/31/2015	49	-3	N/A	5	N/A
12/31/2014	44	-1	N/A	3	N/A
9/30/2014	39	-5	N/A	2	N/A
6/30/2014	35	-6	N/A	-3	N/A
3/31/2014	33	-7	N/A	-2	N/A
12/31/2013	33	-8	N/A	-1	N/A
9/30/2013	31	-6	N/A	-3	N/A
6/30/2013	31	-7	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ICAD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ICAD今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ICAD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ICADの収益 ( 18% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ICADの収益 ( 18% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ICADの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

iCAD 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus revenue estimates fall by 12%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 16%

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

iCAD, Inc. to Report Q1, 2024 Results on May 15, 2024

iCAD, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD, Inc. to Report Q4, 2021 Results on Feb 28, 2022

iCAD: Downside Seems Limited

Consensus EPS estimates fall by 11%

iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially

Price target decreased to US$19.43

Forecast breakeven date pushed back to 2024